Oncimmune Holdings Plc, a leading global innumodiagnostics group, has been awarded the Queen’s Award for Enterprise in Innovation 2022. Regarded as the highest official UK award for British business and now in its 56th year, the Queen’s Award for Enterprise is an annual award which endorses outstanding achievement in innovation. It is awarded to products or services that have been available on the market and can demonstrate outstanding innovation and commercial success for at least two years.
This accolade acknowledges the innovation behind Oncimmune’s immunodiagnostic and discovery technology. This started with EarlyCDT, a blood test which can help identify cancer on average four years earlier than current standard clinical diagnosis, and continues today through Oncimmune’s ImmunoINSIGHTS platform, which enables life science organisations to optimise drug development and delivery, leading to more effective targeting as well as safer treatments for patients.
The ImmunoINSIGHTS core immune-profiling technology is underpinned by a library of over 8,800 immunogenic proteins, one of the largest of its kind, which helps to identify clinical trial participants and patients in clinically relevant subgroups, enabling the development of targeted, more effective treatments with a lower risk of adverse events.
Seneca’s EIS fund invested in Oncimmune in March 21 having been impressed by the Company’s management team, the progress to date and the fundamental technology and potential of the ImmunoINSIGHTS platform.
For more information visit the following links:
